SkyAI, Inc. (SKYAW) company profile
Close on Oct 30, 2026Market cap $127.66MP/E –Yield –
About SkyAI
Finance Services, SIC 6199
Sharps Technology, Inc. is a medical device sales and distribution company that specializes in marketing and distributing syringe products along with related drug-delivery systems. The enterprise previously designed and manufactured a range of conventional and safety syringes for specialty, clinical, and pharmaceutical uses, and it markets remaining inventory to healthcare providers, hospitals, medical supply organizations, and clinics. In addition to its medical distribution business, the company operates a digital asset treasury strategy dedicated to acquiring and holding Solana tokens, engaging in native staking and selective derivative transactions.
The company distributes its medical products across domestic and international markets. Sharps Technology maintains its principal executive offices in Melville, New York. Its operations include treasury oversight functions that coordinate digital asset management alongside third-party advisory partners.
Summary of the business section of SkyAI's latest annual report, written by StockData.
Company profile
Company
- Legal name
- SkyAI, Inc.
- Headquarters
- Melville, NY
- Address
- 105 Maxess Road, Ste. 124 11747
- Phone
- (631) 574-4436
- Website
- skyai.co
- Employees
- 55, Dec 31, 2024
- Industry
- Finance Services
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- PKF OConnor Davies, LLP, New York, New York
Stock & identifiers
- Ticker
- SKYAW
- Other tickers
- SKYA
- Exchange
- Nasdaq
- IPO date
- Apr 15, 2022
- Shares outstanding
- 43M, Aug 4, 2026
- Public float
- $5.57M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-300 reverse, Apr 28, 2025; 1-for-22 reverse, Oct 16, 2024
- SEC CIK
- 1737995
- CUSIP
- 82003F119
- ISIN
- US82003F1194
- FIGI
- BBG016R0TXX5
- EIN
- 82-3751728
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Yuwen Zhang | Chief Investment Officer, Director | 14,040 |
| Andrew R. Crescenzo | Chief Financial Officer, Director | 40,000 |
| Arthur Levine | Chief Financial Officer | – |
| Timothy James Ruemler | Director | 35,218 |
| Brenda Baird Simpson | Director | 20,000 |
| Jason L. Monroe | Director | 80,000 |
| Soren Bo Christiansen | Director | 80,000 |
| Paul K. Danner | Director | 400,000 |
| Robert Michael Hayes | Director | 100,000 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Robert M. Hayes | $1.63M | $150.00K | $547.01K | $890 | $2.33M | +273% |
| Paul K. Danner | $250.13K | $1.00M | $2.21M | – | $3.46M | – |
| Yuwen (Alice) Zhang | $212.50K | – | $2.76M | – | $2.97M | – |
| Andrew R. Crescenzo | $259.90K | $83.75K | $220.79K | $11.04K | $575.47K | +128% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Apr 15, 2022
- Offer price
- $4.25
- Securities offered
- 3,750,000
- Gross proceeds
- $15.94M
- Exchange
- Nasdaq
- First trading day
- Apr 14, 2022
- First-day close
- $2.11-50.3%
- Lock-up ends (est.)
- Oct 11, 2022
“The initial public offering price per Unit is $4.25.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“We have fifty-five full-time employees, two of which are our Chief Executive Officer and Chief Financial Officer, and retain the services of additional personnel, as needed, on an independent contractor basis to support R&D, Finance, Marketing and Regulatory areas.”
Corporate history
Events identified from SEC filings